Personalized medicine for pathological circadian dysfunctions

The recent approval of a therapeutic for a circadian disorder has increased interest in developing additional medicines for disorders characterized by circadian disruption. However, previous experience demonstrates that drug development for central nervous system (CNS) disorders has a high failure r...

Descripción completa

Detalles Bibliográficos
Autores principales: Skelton, Rachel L., Kornhauser, Jon M., Tate, Barbara A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472982/
https://www.ncbi.nlm.nih.gov/pubmed/26150790
http://dx.doi.org/10.3389/fphar.2015.00125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472982/
https://www.ncbi.nlm.nih.gov/pubmed/26150790
http://dx.doi.org/10.3389/fphar.2015.00125

Ejemplares similares